On February 2, 2017, the website TheStreet.com published an article titled "Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial, the Company Raises Money." TheStreet.com reported that investors who purchased in a Stemline stock offering on January 19, 2017 were not told that a day prior to the offering a cancer patient in a clinical trial died from a severe side effect tied to the Company's SL-401 drug.
Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own Stemline shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-stemline-therapeutics-inc-300402899.html
SOURCE Harwood Feffer LLP